Table of Contents

Research Articles

• Research Articles | AuthorChoice

  A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

  Sheau W. Lok, James R. Whittle, François Vaillant, Charis E. Teh, Louisa L. Lo, Antonia N. Policheni, Alice R.T. Bergin, Jayesh Desai, Sarah Ftouni, Luke C. Gandolfo, Danny Liew, He K. Liu, G. Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W. Roberts, Mark A. Rosenthal, Kylie Shackleton, Maria João Silva, Zhen R. Siow, Gordon K. Smyth, Leanne Taylor, Avraham Travers, Belinda Yeo, Miriam M. Yeung, Andjelija Zivanovic Bujak, Sarah-Jane Dawson, Daniel H.D. Gray, Jane E. Visvader and Geoffrey J. Lindeman

  Cancer Discov March 1 2019 9 (3) 354-369; DOI:10.1158/2159-8290.CD-18-1151

  
  

  Combined treatment with tamoxifen and the BCL2 inhibitor venetoclax is safe and shows clinical activity in patients with ER⁺ and BCL2⁺ metastatic breast cancer.

• Research Articles | AuthorChoice

  Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

  Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Prajwal C. Boddu, Mansour Alfayez, Jorge E. Cortes, Marina Konopleva, Farhad Ravandi-Kashani, Elias Jabbour, Tapan Kadia, Graciela M. Nogueras-Gonzalez, Jing Ning, Naveen Pemmaraju, Courtney D. DiNardo, Michael Andreeff, Sherry A. Pierce, Tauna Gordon, Steven M. Kornblau, Wilmer Flores, Zainab Alhamal, Carlos Bueso-Ramos, Jeffrey L. Jorgensen, Keyur P. Patel, Jorge Blando, James P. Allison, Padmanee Sharma and Hagop Kantarjian

  Cancer Discov March 1 2019 9 (3) 370-383; DOI:10.1158/2159-8290.CD-18-0774

  
  

  The addition of immune checkpoint blockade to hypomethylating therapy is safe and effective in patients with acute myeloid leukemia.

• Research Articles | AuthorChoice

  A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

  Alexander Drilon, Siqing Fu, Manish R. Patel, Marwan Fakih, Ding Wang, Anthony J. Olszanski, Daniel Morgensztern, Stephen V. Liu, Byoung Chul Cho, Lyudmila Bazhenova, Cristina P. Rodriguez, Robert C. Doebele, Antoinette Wozniak, Karen L. Reckamp, Tara Seery, Petros Nikolinakos, Zheyi Hu, Jennifer W. Oliver, Denise Trone, Katherine McArthur, Rupal Patel, Pratik S. Multani and Myung-Ju Ahn

  Cancer Discov March 1 2019 9 (3) 384-395; DOI:10.1158/2159-8290.CD-18-0839

  
  

  The VEGFR-sparing multikinase RET inhibitor RXDX-105 exhibits antitumor activity and inhibition of RET in patients with non-KIF5B–RET non–small cell lung cancer.

• Research Articles | AuthorChoice

  ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

  Rani Ojha, Nektaria M. Leli, Angelique Onorati, Shengfu Piao, Ioannis I. Verginadis, Feven Tameire, Vito W. Rebecca, Cynthia I. Chude, Sengottuvelan Murugan, Colin Fennelly, Estela Noguera-Ortega, Charleen T. Chu, Shujing Liu, Xiaowei Xu, Clemens Krepler, Min Xiao, Wei Xu, Zhi Wei, Dennie T. Frederick, Genevieve Boland, Tara C. Mitchell, Giorgos C. Karakousis, Lynn M. Schuchter, Keith T. Flaherty, Gao Zhang, Meenhard Herlyn, Constantinos Koumenis and Ravi K. Amaravadi

  Cancer Discov March 1 2019 9 (3) 396-415; DOI:10.1158/2159-8290.CD-18-0348

  
  

  Combined BRAF and MEK inhibition induces ER translocation of MAPK pathway components, followed by ERK reactivation and induction of autophagy.

• Research Articles

  Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis

  Alessandro Carrer, Sophie Trefely, Steven Zhao, Sydney L. Campbell, Robert J. Norgard, Kollin C. Schultz, Simone Sidoli, Joshua L.D. Parris, Hayley C. Affronti, Sharanya Sivanand, Shaun Egolf, Yogev Sela, Marco Trizzino, Alessandro Gardini, Benjamin A. Garcia, Nathaniel W. Snyder, Ben Z. Stanger and Kathryn E. Wellen

  Cancer Discov March 1 2019 9 (3) 416-435; DOI:10.1158/2159-8290.CD-18-0567

  
  

  Increased utilization of acetyl-CoA promotes plasticity in Kras-mutant pancreatic cells and renders PDAC sensitive to inhibitors of the BET family of proteins and HMG-CoA reductase.

• Research Articles

  Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL

  Agnieszka A. Wendorff, S. Aidan Quinn, Marissa Rashkovan, Chioma J. Madubata, Alberto Ambesi-Impiombato, Mark R. Litzow, Martin S. Tallman, Elisabeth Paietta, Maddalena Paganin, Giuseppe Basso, Julie M. Gastier-Foster, Mignon L. Loh, Raul Rabadan, Pieter Van Vlierberghe and Adolfo A. Ferrando

  Cancer Discov March 1 2019 9 (3) 436-451; DOI:10.1158/2159-8290.CD-18-1005

  
  

  PHF6 loss-of-function is an early event in T-ALL development that facilitates leukemic initiation by promoting HSC expansion and selfrenewal.